The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277 - 300; http://dx.doi.org/10.3322/caac.20073; PMID: 20610543
   PubMed Web of Science ®Google Scholar
• Marchetti C, Pisano C, Facchini G, Bruni GS, Magazzino FP, Losito S, et al. First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther 2010; 10:47 - 60; http://dx.doi.org/10.1586/era.09.167; PMID: 20014885
   PubMed Web of Science ®Google Scholar
• Ricci F, Bernasconi S, Perego P, Ganzinelli M, Russo G, Bono F, et al. Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. Cell Cycle 2012; 11:1966 - 76; http://dx.doi.org/10.4161/cc.20308; PMID: 22544328
   PubMed Web of Science ®Google Scholar
• Cho KR. Murine models of ovarian cancer for preclinical testing of targeted therapeutics: has their time arrived?. Cell Cycle 2012; 11:430 - 1; http://dx.doi.org/10.4161/cc.11.3.19275; PMID: 22262181
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683 - 92; http://dx.doi.org/10.1016/j.cell.2007.01.029; PMID: 17320506
   PubMed Web of Science ®Google Scholar
• Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Minireview: epigenetic changes in ovarian cancer. Endocrinology 2009; 150:4003 - 11; http://dx.doi.org/10.1210/en.2009-0404; PMID: 19574400
   PubMed Web of Science ®Google Scholar
• Momparler RL. Cancer epigenetics. Oncogene 2003; 22:6479 - 83; http://dx.doi.org/10.1038/sj.onc.1206774; PMID: 14528271
   PubMed Web of Science ®Google Scholar
• Maier S, Dahlstroem C, Haefliger C, Plum A, Piepenbrock C. Identifying DNA methylation biomarkers of cancer drug response. Am J Pharmacogenomics 2005; 5:223 - 32; http://dx.doi.org/10.2165/00129785-200505040-00003; PMID: 16078859
   PubMedGoogle Scholar
• Szyf M, Pakneshan P, Rabbani SA. DNA demethylation and cancer: therapeutic implications. Cancer Lett 2004; 211:133 - 43; http://dx.doi.org/10.1016/j.canlet.2004.04.009; PMID: 15219937
   PubMed Web of Science ®Google Scholar
• Bauerschlag DO, Ammerpohl O, Bräutigam K, Schem C, Lin Q, Weigel MT, et al. Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Oncology 2011; 80:12 - 20; http://dx.doi.org/10.1159/000327746; PMID: 21577013
   PubMed Web of Science ®Google Scholar
• Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics 2008; 1:47; http://dx.doi.org/10.1186/1755-8794-1-47; PMID: 18826610
   PubMed Web of Science ®Google Scholar
• Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009; 2:34; http://dx.doi.org/10.1186/1755-8794-2-34; PMID: 19505326
   PubMed Web of Science ®Google Scholar
• Keita M, Wang Z-Q, Pelletier J-F, Bachvarova M, Plante M, Gregoire J, et al. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. Gynecol Oncol 2013; 128:356 - 63; PMID: 23219462
   PubMed Web of Science ®Google Scholar
• Huang X, Peng JW, Speck NA, Bushweller JH. Solution structure of core binding factor beta and map of the CBF alpha binding site. Nat Struct Biol 1999; 6:624 - 7; http://dx.doi.org/10.1038/10670; PMID: 10404216
   PubMedGoogle Scholar
• Wang CQ, Jacob B, Nah GS, Osato M. Runx family genes, niche, and stem cell quiescence. Blood Cells Mol Dis 2010; 44:275 - 86; http://dx.doi.org/10.1016/j.bcmd.2010.01.006; PMID: 20144877
   PubMed Web of Science ®Google Scholar
• Wong WF, Kohu K, Chiba T, Sato T, Satake M. Interplay of transcription factors in T-cell differentiation and function: the role of Runx. Immunology 2011; 132:157 - 64; http://dx.doi.org/10.1111/j.1365-2567.2010.03381.x; PMID: 21091910
   PubMed Web of Science ®Google Scholar
• Chuang LS, Lai SK, Murata-Hori M, Yamada A, Li HY, Gunaratne J, et al. RUNX3 interactome reveals novel centrosomal targeting of RUNX family of transcription factors. Cell Cycle 2012; 11:1938 - 47; http://dx.doi.org/10.4161/cc.20278; PMID: 22544322
   PubMed Web of Science ®Google Scholar
• Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84:321 - 30; http://dx.doi.org/10.1016/S0092-8674(00)80986-1; PMID: 8565077
   PubMed Web of Science ®Google Scholar
• Kilbey A, Terry A, Jenkins A, Borland G, Zhang Q, Wakelam MJ, et al. Runx regulation of sphingolipid metabolism and survival signaling. Cancer Res 2010; 70:5860 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-10-0726; PMID: 20587518
   PubMed Web of Science ®Google Scholar
• Scheitz CJ, Tumbar T. New insights into the role of Runx1 in epithelial stem cell biology and pathology. J Cell Biochem 2012; http://dx.doi.org/10.1002/jcb.24453; PMID: 23150456
   PubMed Web of Science ®Google Scholar
• Wotton S, Stewart M, Blyth K, Vaillant F, Kilbey A, Neil JC, et al. Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. Cancer Res 2002; 62:7181 - 5; PMID: 12499254
   PubMed Web of Science ®Google Scholar
• Robinson HM, Broadfield ZJ, Cheung KL, Harewood L, Harris RL, Jalali GR, et al. Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2003; 17:2249 - 50; http://dx.doi.org/10.1038/sj.leu.2403140
   PubMed Web of Science ®Google Scholar
• Planagumà J, Liljeström M, Alameda F, Bützow R, Virtanen I, Reventós J, et al. Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. Hum Pathol 2011; 42:57 - 67; http://dx.doi.org/10.1016/j.humpath.2010.01.025; PMID: 20970160
   PubMed Web of Science ®Google Scholar
• Ho Sui SJ, Mortimer JR, Arenillas DJ, Brumm J, Walsh CJ, Kennedy BP, et al. oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res 2005; 33:3154 - 64; http://dx.doi.org/10.1093/nar/gki624; PMID: 15933209
   PubMed Web of Science ®Google Scholar
• Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005; 5:376 - 87; http://dx.doi.org/10.1038/nrc1607; PMID: 15864279
   PubMed Web of Science ®Google Scholar
• Wotton SF, Blyth K, Kilbey A, Jenkins A, Terry A, Bernardin-Fried F, et al. RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53. Oncogene 2004; 23:5476 - 86; http://dx.doi.org/10.1038/sj.onc.1207729; PMID: 15133495
   PubMed Web of Science ®Google Scholar
• Wolyniec K, Wotton S, Kilbey A, Jenkins A, Terry A, Peters G, et al. RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress. Oncogene 2009; 28:2502 - 12; http://dx.doi.org/10.1038/onc.2009.101; PMID: 19448675
   PubMed Web of Science ®Google Scholar
• Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 2002; 8:743 - 50; http://dx.doi.org/10.1038/nm726; PMID: 12091906
   PubMed Web of Science ®Google Scholar
• Mikhail FM, Sinha KK, Saunthararajah Y, Nucifora G. Normal and transforming functions of RUNX1: a perspective. J Cell Physiol 2006; 207:582 - 93; http://dx.doi.org/10.1002/jcp.20538; PMID: 16250015
   PubMed Web of Science ®Google Scholar
• Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002; 2:502 - 13; http://dx.doi.org/10.1038/nrc840; PMID: 12094236
   PubMed Web of Science ®Google Scholar
• Roumier C, Fenaux P, Lafage M, Imbert M, Eclache V, Preudhomme C. New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2003; 17:9 - 16; http://dx.doi.org/10.1038/sj.leu.2402766
   PubMed Web of Science ®Google Scholar
• Yanagida M, Osato M, Yamashita N, Liqun H, Jacob B, Wu F, et al. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. Oncogene 2005; 24:4477 - 85; http://dx.doi.org/10.1038/sj.onc.1208675; PMID: 15856017
   PubMed Web of Science ®Google Scholar
• Janes KA. RUNX1 and its understudied role in breast cancer. Cell Cycle 2011; 10:3461 - 5; http://dx.doi.org/10.4161/cc.10.20.18029; PMID: 22024923
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486:353 - 60; PMID: 22722193
   PubMed Web of Science ®Google Scholar
• Fijneman RJ, Anderson RA, Richards E, Liu J, Tijssen M, Meijer GA, et al. Runx1 is a tumor suppressor gene in the mouse gastrointestinal tract. Cancer Sci 2012; 103:593 - 9; http://dx.doi.org/10.1111/j.1349-7006.2011.02189.x; PMID: 22171576
   PubMed Web of Science ®Google Scholar
• Dulak AM, Schumacher SE, van Lieshout J, Imamura Y, Fox C, Shim B, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012; 72:4383 - 93; http://dx.doi.org/10.1158/0008-5472.CAN-11-3893; PMID: 22751462
   PubMed Web of Science ®Google Scholar
• Planagumà J, Díaz-Fuertes M, Gil-Moreno A, Abal M, Monge M, García A, et al. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res 2004; 64:8846 - 53; http://dx.doi.org/10.1158/0008-5472.CAN-04-2066; PMID: 15604243
   PubMed Web of Science ®Google Scholar
• Doll A, Gonzalez M, Abal M, Llaurado M, Rigau M, Colas E, et al. An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis. Int J Cancer 2009; 125:257 - 63; http://dx.doi.org/10.1002/ijc.24330; PMID: 19384951
   PubMed Web of Science ®Google Scholar
• Scheitz CJ, Lee TS, McDermitt DJ, Tumbar T. Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer. EMBO J 2012; 31:4124 - 39; http://dx.doi.org/10.1038/emboj.2012.270; PMID: 23034403
   PubMed Web of Science ®Google Scholar
• Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, et al. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol 2013; 128:506 - 11; http://dx.doi.org/10.1016/j.ygyno.2012.11.029; PMID: 23200915
   PubMed Web of Science ®Google Scholar
• Yeh HY, Cheng SW, Lin YC, Yeh CY, Lin SF, Soo VW. Identifying significant genetic regulatory networks in the prostate cancer from microarray data based on transcription factor analysis and conditional independency. BMC Med Genomics 2009; 2:70; http://dx.doi.org/10.1186/1755-8794-2-70; PMID: 20025723
   PubMed Web of Science ®Google Scholar
• Slattery ML, Lundgreen A, Herrick JS, Caan BJ, Potter JD, Wolff RK. Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and riskof colon and rectal cancer: additional support for a TGF-β-signaling pathway. Carcinogenesis 2011; 32:318 - 26; http://dx.doi.org/10.1093/carcin/bgq245; PMID: 21088106
   PubMed Web of Science ®Google Scholar
• Xu K, Zhou Y, Qiu W, Liu X, Xia M, Liu L, et al. Activating transcription factor 3 (ATF3) promotes sublytic C5b-9-induced glomerular mesangial cells apoptosis through up-regulation of Gadd45α and KLF6 gene expression. Immunobiology 2011; 216:871 - 81; http://dx.doi.org/10.1016/j.imbio.2011.02.005; PMID: 21396734
   PubMed Web of Science ®Google Scholar
• Ehrhardt H, Schrembs D, Moritz C, Wachter F, Haldar S, Graubner U, et al. Optimized anti-tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule. Blood 2011; 118:6123 - 31; http://dx.doi.org/10.1182/blood-2010-02-269811; PMID: 21926351
   PubMed Web of Science ®Google Scholar
• Porter LA, Singh G, Lee JM. Abundance of cyclin B1 regulates gamma-radiation-induced apoptosis. Blood 2000; 95:2645 - 50; PMID: 10753846
   PubMed Web of Science ®Google Scholar
• Zerbini LF, Wang Y, Czibere A, Correa RG, Cho JY, Ijiri K, et al. NF-kappa B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45alpha and gamma is essential for cancer cell survival. Proc Natl Acad Sci USA 2004; 101:13618 - 23; http://dx.doi.org/10.1073/pnas.0402069101; PMID: 15353598
   PubMed Web of Science ®Google Scholar
• Pollock AS, Turck J, Lovett DH. The prodomain of interleukin 1alpha interacts with elements of the RNA processing apparatus and induces apoptosis in malignant cells. FASEB J 2003; 17:203 - 13; http://dx.doi.org/10.1096/fj.02-0602com; PMID: 12554699
   PubMed Web of Science ®Google Scholar
• Kim JE, Kim SJ, Jeong HW, Lee BH, Choi JY, Park RW, et al. RGD peptides released from beta ig-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis. Oncogene 2003; 22:2045 - 53; http://dx.doi.org/10.1038/sj.onc.1206269; PMID: 12673209
   PubMed Web of Science ®Google Scholar
• Yan C, Boyd DD. ATF3 regulates the stability of p53: a link to cancer. Cell Cycle 2006; 5:926 - 9; http://dx.doi.org/10.4161/cc.5.9.2714; PMID: 16628010
   PubMed Web of Science ®Google Scholar
• Glinsky GV. Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle 2006; 5:1208 - 16; http://dx.doi.org/10.4161/cc.5.11.2796; PMID: 16760651
   PubMed Web of Science ®Google Scholar
• Hamstra DA, Pagé M, Maybaum J, Rehemtulla A. Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs. Cancer Res 2000; 60:657 - 65; PMID: 10676650
   PubMed Web of Science ®Google Scholar
• Laronga C, Yang HY, Neal C, Lee MH. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 2000; 275:23106 - 12; http://dx.doi.org/10.1074/jbc.M905616199; PMID: 10767298
   PubMed Web of Science ®Google Scholar
• Dhar S, Squire JA, Hande MP, Wellinger RJ, Pandita TK. Inactivation of 14-3-3sigma influences telomere behavior and ionizing radiation-induced chromosomal instability. Mol Cell Biol 2000; 20:7764 - 72; http://dx.doi.org/10.1128/MCB.20.20.7764-7772.2000; PMID: 11003671
   PubMed Web of Science ®Google Scholar
• Meng S, Arbit T, Veeriah S, Mellinghoff IK, Fang F, Vivanco I, et al. 14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition. Cell Cycle 2009; 8:2238 - 46; http://dx.doi.org/10.4161/cc.8.14.8998; PMID: 19502805
   PubMed Web of Science ®Google Scholar
• Fukai N, Shichiri M, Ozawa N, Matsushita M, Hirata Y. Coexpression of calcitonin receptor-like receptor and receptor activity-modifying protein 2 or 3 mediates the antimigratory effect of adrenomedullin. Endocrinology 2003; 144:447 - 53; http://dx.doi.org/10.1210/en.2002-220463; PMID: 12538603
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009; 30:85 - 94; http://dx.doi.org/10.1016/j.tips.2008.11.002; PMID: 19110321
   PubMed Web of Science ®Google Scholar
• Iozzo RV, Buraschi S, Genua M, Xu SQ, Solomides CC, Peiper SC, et al. Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem 2011; 286:34712 - 21; http://dx.doi.org/10.1074/jbc.M111.262766; PMID: 21840990
   PubMed Web of Science ®Google Scholar
• Korah RM, Sysounthone V, Golowa Y, Wieder R. Basic fibroblast growth factor confers a less malignant phenotype in MDA-MB-231 human breast cancer cells. Cancer Res 2000; 60:733 - 40; PMID: 10676661
   PubMed Web of Science ®Google Scholar
• Plante I, Stewart MK, Barr K, Allan AL, Laird DW. Cx43 suppresses mammary tumor metastasis to the lung in a Cx43 mutant mouse model of human disease. Oncogene 2011; 30:1681 - 92; http://dx.doi.org/10.1038/onc.2010.551; PMID: 21151177
   PubMed Web of Science ®Google Scholar
• Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood 1996; 87:1 - 13; PMID: 8547630
   PubMed Web of Science ®Google Scholar
• Rivera A, Mavila A, Bayless KJ, Davis GE, Maxwell SA. Cyclin A1 is a p53-induced gene that mediates apoptosis, G2/M arrest, and mitotic catastrophe in renal, ovarian, and lung carcinoma cells. Cell Mol Life Sci 2006; 63:1425 - 39; http://dx.doi.org/10.1007/s00018-006-5521-5; PMID: 16799873
   PubMed Web of Science ®Google Scholar
• Nash MA, Deavers MT, Freedman RS. The expression of decorin in human ovarian tumors. Clin Cancer Res 2002; 8:1754 - 60; PMID: 12060613
   PubMed Web of Science ®Google Scholar
• Hollander MC, Kovalsky O, Salvador JM, Kim KE, Patterson AD, Haines DC, et al. Dimethylbenzanthracene carcinogenesis in Gadd45a-null mice is associated with decreased DNA repair and increased mutation frequency. Cancer Res 2001; 61:2487 - 91; PMID: 11289119
   PubMed Web of Science ®Google Scholar
• Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, Moriya T, et al. Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res 2004; 10:2687 - 93; http://dx.doi.org/10.1158/1078-0432.CCR-03-0510; PMID: 15102672
   PubMed Web of Science ®Google Scholar
• Baranello C, Mariani M, Andreoli M, Fanelli M, Martinelli E, Ferrandina G, et al. Adrenomedullin in ovarian cancer: foe in vitro and friend in vivo?. PLoS ONE 2012; 7:e40678; http://dx.doi.org/10.1371/journal.pone.0040678; PMID: 22859951
   PubMedGoogle Scholar
• Syed V, Mukherjee K, Lyons-Weiler J, Lau KM, Mashima T, Tsuruo T, et al. Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling. Oncogene 2005; 24:1774 - 87; http://dx.doi.org/10.1038/sj.onc.1207991; PMID: 15674352
   PubMed Web of Science ®Google Scholar
• Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, et al. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Int J Gynecol Pathol 2011; 30:205 - 17; http://dx.doi.org/10.1097/PGP.0b013e3182063e71; PMID: 21464733
   PubMed Web of Science ®Google Scholar
• Li J, Wood WH 3rd, Becker KG, Weeraratna AT, Morin PJ. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene 2007; 26:2860 - 72; http://dx.doi.org/10.1038/sj.onc.1210086; PMID: 17072341
   PubMed Web of Science ®Google Scholar
• Chou JL, Chen LY, Lai HC, Chan MW. TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy. Expert Opin Ther Targets 2010; 14:1213 - 23; http://dx.doi.org/10.1517/14728222.2010.525353; PMID: 20925461
   PubMed Web of Science ®Google Scholar
• McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, et al. Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest 2011; 121:3206 - 19; http://dx.doi.org/10.1172/JCI45273; PMID: 21737876
   PubMed Web of Science ®Google Scholar
• Symowicz J, Adley BP, Gleason KJ, Johnson JJ, Ghosh S, Fishman DA, et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 2007; 67:2030 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-06-2808; PMID: 17332331
   PubMed Web of Science ®Google Scholar
• Rask K, Nilsson A, Brännström M, Carlsson P, Hellberg P, Janson PO, et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer 2003; 89:1298 - 304; http://dx.doi.org/10.1038/sj.bjc.6601265; PMID: 14520463
   PubMed Web of Science ®Google Scholar
• Crijns AP, de Graeff P, Geerts D, Ten Hoor KA, Hollema H, van der Sluis T, et al. MEIS and PBX homeobox proteins in ovarian cancer. Eur J Cancer 2007; 43:2495 - 505; http://dx.doi.org/10.1016/j.ejca.2007.08.025; PMID: 17949970
   PubMed Web of Science ®Google Scholar
• Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004; 10:3291 - 300; http://dx.doi.org/10.1158/1078-0432.CCR-03-0409; PMID: 15161682
   PubMed Web of Science ®Google Scholar
• Elattar A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P, et al. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol 2012; 124:142 - 7; http://dx.doi.org/10.1016/j.ygyno.2011.09.004; PMID: 22001143
   PubMed Web of Science ®Google Scholar
• Zecchini S, Bombardelli L, Decio A, Bianchi M, Mazzarol G, Sanguineti F, et al. The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Mol Med 2011; 3:480 - 94; http://dx.doi.org/10.1002/emmm.201100152; PMID: 21739604
   PubMed Web of Science ®Google Scholar
• Tan Y, Cheung M, Pei J, Menges CW, Godwin AK, Testa JR. Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling. Cancer Res 2010; 70:9197 - 206; http://dx.doi.org/10.1158/0008-5472.CAN-10-1568; PMID: 21045156
   PubMed Web of Science ®Google Scholar
• Tanwar PS, Kaneko-Tarui T, Lee HJ, Zhang L, Teixeira JM. PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression. Carcinogenesis 2012; 33:2351 - 61; http://dx.doi.org/10.1093/carcin/bgs405; PMID: 22962306
   PubMed Web of Science ®Google Scholar
• Meng Y, Gu C, Wu Z, Zhao Y, Si Y, Fu X, et al. Id2 promotes the invasive growth of MCF-7 and SKOV-3 cells by a novel mechanism independent of dimerization to basic helix-loop-helix factors. BMC Cancer 2009; 9:75; http://dx.doi.org/10.1186/1471-2407-9-75; PMID: 19257909
   PubMed Web of Science ®Google Scholar
• Karam A, Dorigo O. MMPs in ovarian cancer as therapeutic targets. Anticancer Agents Med Chem 2012; 12:764 - 72; http://dx.doi.org/10.2174/187152012802650174; PMID: 22292752
   PubMed Web of Science ®Google Scholar
• Lu ZY, Dong R, Li D, Li WB, Xu FQ, Geng Y, et al. SNAI1 overexpression induces stemness and promotes ovarian cancer cell invasion and metastasis. Oncol Rep 2012; 27:1587 - 91; PMID: 22344746
   PubMed Web of Science ®Google Scholar
• Chen J, Wang M, Xi B, Xue J, He D, Zhang J, et al. SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer. PLoS ONE 2012; 7:e42413; http://dx.doi.org/10.1371/journal.pone.0042413; PMID: 22879971
   PubMedGoogle Scholar
• Nicosia SV, Bai W, Cheng JQ, Coppola D, Kruk PA. Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am 2003; 17:927 - 43; http://dx.doi.org/10.1016/S0889-8588(03)00056-X; PMID: 12959183
   PubMed Web of Science ®Google Scholar
• Li W, Xu S, Lin S, Zhao W. Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. J Biomed Biotechnol 2012; 2012:456534; http://dx.doi.org/10.1155/2012/456534; PMID: 23093845
   PubMed Web of Science ®Google Scholar
• Zhang S, Wei L, Zhang A, Zhang L, Yu H. RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines. OMICS 2009; 13:307 - 11; http://dx.doi.org/10.1089/omi.2009.0030; PMID: 19645591
   PubMed Web of Science ®Google Scholar
• Lee CW, Chuang LS, Kimura S, Lai SK, Ong CW, Yan B, et al. RUNX3 functions as an oncogene in ovarian cancer. Gynecol Oncol 2011; 122:410 - 7; http://dx.doi.org/10.1016/j.ygyno.2011.04.044; PMID: 21612813
   PubMed Web of Science ®Google Scholar
• Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000; 92:1534 - 5; http://dx.doi.org/10.1093/jnci/92.18.1534; PMID: 10995813
   PubMed Web of Science ®Google Scholar
• L’Espérance S, Bachvarova M, Tetu B, Mes-Masson AM, Bachvarov D. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 2008; 9:99; http://dx.doi.org/10.1186/1471-2164-9-99; PMID: 18302766
   PubMed Web of Science ®Google Scholar
• Mercier PL, Bachvarova M, Plante M, Gregoire J, Renaud MC, Ghani K, et al. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol 2011; 5:438 - 53; http://dx.doi.org/10.1016/j.molonc.2011.07.003; PMID: 21856257
   PubMed Web of Science ®Google Scholar
• Tetu B, Popa I, Bairati I, L'Esperance S, Bachvarova M, Plante M, et al. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Modern pathology: an official journal of the United States and Canadian Academy of Pathology. Inc 2008; 21:1002 - 10
   Google Scholar
• Lai SR, Andrews LG, Tollefsbol TO. RNA interference using a plasmid construct expressing short-hairpin RNA. Methods Mol Biol 2007; 405:31 - 7; http://dx.doi.org/10.1007/978-1-60327-070-0_4; PMID: 18369815
   PubMedGoogle Scholar